JAK2 and triple-negative breast carcinoma: Balko JM proposed that JAK2 might be a therapeutic target for triple-negative breast cancers with amplification of JAK2, and specific JAK2 inhibitors could be used in combination with chemotherapy to inhibit this process, to reduce tumor-initiating stem cell-like cells and inhibit the tumor growth.